SS-31 50mg

This guide covers the 50mg vial format of SS-31 — the same mitochondria-targeting tetrapeptide described in the dedicated 10mg guide (D-Arg-Dmt-Lys-Phe-NH2, MW ~639.8 g/mol), supplied at a substantially larger vial size. The mechanism, structural details, and proposed cardiolipin-binding pharmacology are identical to the 10mg form. What this guide adds is the cohort-scale research-protocol context that matters when SS-31 is the consumable in a multi-subject animal study, a large in-vitro screen, or any other design that exhausts a 10mg vial faster than its post-reconstitution stability window.

SS-31 research at cohort scale — particularly preclinical animal studies running multiple subjects across multiple time points — can consume substantially more peptide than the 10mg format supplies. The choice between 10mg and 50mg is essentially economic plus stability: reconstituting one 50mg vial produces less freeze-thaw exposure across a given total peptide volume than reconstituting five 10mg vials sequentially. For low-throughput cell-culture experiments or single-protocol pilots, the 10mg vial is usually adequate; for sustained cohort work, the 50mg format reduces handling overhead.

SS-31 50mg is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

SS-31 carries three positive charges at physiological pH, which gives it strong affinity for anionic surfaces — including untreated glassware and some plastic vessels. Working solutions prepared at low concentrations can lose meaningful amounts of peptide to container walls before reaching the experimental system. At cohort scale, where consistency across many parallel preparations matters more than for one-off experiments, this surface-adhesion behavior is worth controlling for. Researchers preparing stock and working solutions from the 50mg vial should consider pre-passivated polypropylene tubes, surfactant additives where compatible with the assay, and consistent vessel handling across the cohort.

Every batch of MHS Longevity SS-31 50mg is submitted to an independent third-party laboratory before release — the same HPLC + Mass Spectrometry protocol applied to the 10mg vial, with the same 99%+ purity threshold:

Lyophilized SS-31 at -20°C is stable across reasonable timeframes regardless of vial size. The handling change for the 50mg vial is in the post-reconstitution timeline: more total peptide in solution means more material to either use quickly or aliquot for staged use. Single-use aliquoting at the time of reconstitution is good practice for any SS-31 vial size and particularly worth the discipline for the 50mg format. Standard aseptic technique applies during reconstitution.